Stock AnalizAlnylam Pharmaceuticals (ALNY) earnings for the quarter ended September 2026: EPS beats estimates
Alnylam Pharmaceuticals reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at $16.26 against the analysts’ average forecast of $2.25, a beat of 623.0%.
Revenue for the quarter was $1.46 billion, up 16.7% from $1.25 billion in the same quarter a year earlier.
The market’s verdict: the stock fell 25.1% on the first trading day after the report.
The last four quarters
Alnylam Pharmaceuticals has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $16.26 | $2.25 | +623.0% | +17% | −25.1% |
| Jun 2026 | $1.84 | $2.14 | −14.2% | +67% | −28.3% |
| Mar 2026 | $1.99 | $1.47 | +35.3% | — | −1.7% |
| Sep 2025 | $2.90 | $1.75 | +66.1% | +149% | −5.3% |
What comes next
Analysts expect EPS of $2.42 for the next quarter on average and $22.68 for the fiscal year ending December 31, 2026.
The average analyst price target is $299.96, 82% above the current price of $165.04.
Valuation and score
Alnylam Pharmaceuticals scores 2.4 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 8.6, and its intrinsic value under moderate assumptions is about 34% above the current market value. Full Alnylam Pharmaceuticals analysis with 10 years of financials
Frequently asked questions
What was Alnylam Pharmaceuticals’s EPS for the quarter ended September 2026?
$16.26 adjusted per share, against an analyst consensus of $2.25.
How much revenue did Alnylam Pharmaceuticals report?
$1.46 billion, up 16.7% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.